NCT04542304

Efficacy of Diuretics in Kidney Disease

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will determine the efficacy of diuretics in patients with chronic kidney disease.

Detailed description

Participants with chronic kidney disease will undergo two 1-week study periods (single-dose diuretic versus single-dose placebo) separated by 1-2 weeks of washout in a cross-over design. Blood and urine samples will be collected at the end of each study period to determine the effect on urine output and to assess the kidney clearance and levels of uremic solute. Participants will weigh themselves daily.

Conditions

• Chronic Kidney Disease
• End Stage Renal Disease

Interventions

Type	Name	Description
DRUG	Metolazone	Participants receive a single dose of metolazone.
DRUG	Placebo	Participants receive a single dose of placebo to match metolazone.

Timeline

• Start date: 2021-03-01
• Primary completion: 2023-06-15
• Completion: 2023-06-15
• First posted: 2020-09-09
• Last updated: 2025-06-05
• Results posted: 2025-06-05

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study